Second-Line Treatment Strategies for RAS/RAF Wild-Type Colorectal Cancer
This comparative effectiveness study investigates anti–vascular endothelial growth factor vs anti–epidermal growth factor receptor therapy in second-line treatment among patients with RAS/RAF wild-type, right-sided cancer.